| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| cv-9201 | apoptosis inhibitor survivin | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | phase 1/2 | unknown |
| cv-9201 | cancer/testis antigen 1 | NA | Clinical trial target | TTD | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | phase 1/2 | unknown |
| cv-9201 | cancer/testis antigen mage-c1/ct7 | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | phase 1/2 | unknown |
| cv-9201 | melanoma-associated antigen c2 | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | phase 1/2 | unknown |
| cv-9201 | oncotrophoblast glycoprotein 5t4 | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | phase 1/2 | unknown |
| click here to return to the previous page | ||||||||